Can a 'rediscovered' drug from India make it big in US immunology space? Dan Bradbury and his team at Equillium want to prove yes
Biotech companies typically knock on Nasdaq’s doors with several rounds of financing under their belt. Equillium, however, went straight for it.
Having reaped a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
